Simultaneous Quantitative Determination of Metoprolol, Atorvastatin and Ramipril in Capsules by a Validated Stability-Indicating RP-UPLC Method by Seshadri, Raja Kumar et al.
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
Simultaneous Quantitative Determination of 
Metoprolol, Atorvastatin and Ramipril  
in Capsules by a Validated  
Stability-Indicating RP-UPLC Method 
Raja Kumar SESHADRI * 
1, Makarand Madhukar DESAI 
1,  
Thummala Veera RAGHAVARAJU 
1, Deepa KRISHNAN 
1,  
Dama Venugopala RAO 
1, Ivon Elisha CHAKRAVARTHY 
2 
1 Analytical Research and Development, Integrated Product Development, Dr. Reddy’s Laboratories Ltd., 
Bachupally, Hyderabad-500 072, India. 
2 Department of Chemistry, Rayalaseema University, Kurnool-518002, A.P., India. 
* Corresponding author. E-mail: rajakumars@drreddys.com (R. K. Seshadri) 
Sci Pharm. 2010; 78: 821–834        doi:10.3797/scipharm.1004-14 
Published:   August 24
th  2010    Received:    April  18
th 2010 
Accepted:   August 24
th 2010 
This article is available from: http://dx.doi.org/10.3797/scipharm.1004-14 
© Seshadri et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
A simple ultra performance liquid chromatographic (UPLC) method has been 
developed for the simultaneous estimation of Metoprolol (MT), Atorvastatin (AT) 
and Ramipril (RM) from capsule dosage form. The method was developed 
using Zorbax® XDB-C18 (4.6 mm x 50 mm, 1.8 μm) column with a mobile 
phase consisting of 0.06% ortho phosphoric acid in Milli Q® water having an ion 
pair reagent, 0.0045 M Sodium lauryl sulphate as buffer, at ratio of buffer: 
Acetonitrile (50:50 v/v), at 55°C column temperature with a flow rate of 1.0 
ml/min. Detection was carried out with ultra-violet detection at 210 nm for RM, 
MT and AT respectively. The retention times were about 1.3, 2.1 and 2.6 min for 
MT, AT and RM respectively, the method was validated for linearity, accuracy, 
precision, specificity, robustness and ruggedness. The % mean recoveries are 
101.9, 102.1 and 101.4 for MT, AT and RM respectively. The method was found 
to be rugged and robust and can be successfully used to determine the three 
drugs and its combinations. 
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Introduction 
Ramipril (RM) is a potent and specific angiotensin-converting enzyme (ACE) inhibitor that 
catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II 
which also simulates the secretion of aldosterone by adrenal cortex leading to vasopressor 
activity. Thus role of these ACE inhibitors is to inhibit the last step of the biosynthesis of 
angiotensin II and therefore causing a general vasodilatation and lowering of blood 
pressure [1–3]. Atorvastatin calcium (AT) [4] is a lipid lowering drug [5,  6], used for 
treatment of hypercholesterolemia. Metoprolol succinate (MT) acts as a beta-adrenergic 
blocking agent, which reduces chest pain and lowers high blood pressure [2,  7].The 
chemical structures of RM, AT and MT are shown in Fig. 1. 
Name Structure  IUPAC  name 
Ramipril  N
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(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-
(ethoxycarbonyl)-3-phenylpropyl]-
amino}propanoyl]octahydrocyclo-
penta[b]pyrrole-2-carboxylic acid 
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calcium bis{(3R,5R)-7-[2-(4-fluoro-
phenyl)-5-(1-methylethyl)-3-phenyl-
4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-
3,5-dihydroxyheptanoate} 
Metoprolol 
succinate 
N
H
O
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O
O
O
O H
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1-[4-(2-methoxyethyl)phenoxy]-3-
[(1-methylethyl)amino]propan-2-ol 
butanedioate (2:1) (salt) 
Fig.1.   Chemical structures of RM, AT and MT 
Many dosage forms of Metoprolol, Atorvastatin and Ramipril are available in market as a 
single or as combination dosage form with other drugs for effective therapy. As an 
individual molecule Atorvastatin shows effectiveness in lowering lipid levels in condition of 
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recognized as a causative factor in the development of atherosclerosis and hypertension, 
treatment with a beta-adrenergic blocking agent Metoprolol which is known to reduce the 
chest pain and lowering the high blood pressure also have antiatherosclerotic effects and 
Ramipril ACE (angiotensin converting enzyme) will always be a beneficial point for the 
patients by controlling hypertension, angina associated with dyslipidemia and metabolic 
syndrome. Hence these three combination formula is developed as once daily dosage 
form. 
Dr. Reddy’s is the first pharmaceutical company to develop this unique three-in-one 
combination product containing RM, AT and MT which is unique and has got the approval 
from Drug Controller General of India (DCGI), the Brand name of the product is Reviro. 
Literature survey revealed several analytical methods such as UV Spectrophotometer   
[8–10], Liquid Chromatography [11–24], HP-TLC [25], LC-MS [26], UPLC [27, 28] Spectro-
fluorimetry [29, 30] have been reported for the determination of Metoprolol, Atorvastatin 
and Ramipril individually and in combination with different pharmaceutical dosage forms 
and biological samples [31] 
Till date, to the best of our knowledge, no method has been reported in the literature for 
simultaneous determination of MT, AT and RM in oral dosage formulation. It is felt 
necessary to develop a stability indicating assay method for three compounds 
simultaneously.  
Metoprolol impurity C is official in British Pharmacopoeia [32], Metoprolol diol impurity is a 
degradation product identified and completely characterized by using IR, Mass and NMR. 
Ramipril impurities D, E and K are official in British Pharmacopoeia [33]. Atorvastatin 
impurities lactone and hydroxyl epoxy oxazinine are the degradation products, isolated 
and characterized inhouse by using IR, Mass and NMR.  
Results and Discussion 
Optimization of chromatographic conditions 
The HPLC method is optimized with a view to develop a stability indicating Assay. A 
stability-indicating assay method should accurately measure the active ingredients, without 
interference from degradation products, process impurities, excipients, or other potential 
impurities. The key objective of the method is to get the separation of all potential 
impurities of MT, AT and RM from their analyte peaks. Pure drug along with its related 
impurities were injected in Ramipril capsules BP method, it was observed that Atorvastatin 
peak shape is not symmetric and Atorvastatin major degradants Lactone and Hydroxyl 
epoxy oxazinine eluted after 20 min. Subsequently Metoprolol tablets USP method was 
evaluated for separation of RM, AT and MT and its respective impurities. In the metoprolol 
method, the Atorvastatin peak eluted at 91 min and also peak fronting is observed for 
Ramipril, Atorvastatin peaks. 
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S.No Name  Structure  IUPAC  name 
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ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-
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pyrrole-2-carboxylic acid 
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(2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-
1,4-dioxodecahydro-2H-cyclopenta-
[4,5]pyrrolo[1,2-a]pyrazin-2-yl]-4-
phenylbutanoic acid 
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5-(4-fluorophenyl)-1-{2-[(2R,4R)-4-
hydroxy-6-oxotetrahydro-2H-pyran-2-
yl]ethyl}-2-(1-methylethyl)-N,4-
diphenyl-1H-pyrrole-3-carboxamide 
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4-[1b-(4-fluorophenyl)-7-hydroxy-7-
(1-methylethyl)-1a-phenyl-7a-
(phenylcarbamoyl)hexahydro-3H-
oxireno[3,4]pyrrolo[2,1-b][1,3]oxazin-
3-yl]-3-hydroxybutanoic acid 
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(±)-4-{2-hydroxy-3-[(1-methylethyl)-
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(±)-3-[4-(2-methoxyethyl)phenoxy]-
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To develop a new method, the pure drug along with its related impurities were injected in 
different solvent systems containing sodium lauryl sulfate and orthophosphoric acid along 
with various ratios of organic modifiers acetonitrile and methanol on a C8 column. The 
impurities and degradants pertaining to RM, AT and MT active moieties were monitored at 
wavelength of 210 nm. Further, 0.06% ortho phosphoric acid in Milli-Q water was used as 
buffer having an ion pair reagent, 0.045 M sodium lauryl sulfate in the mobile phase to 
achieve effective separation between impurities and the analyte peaks. Buffer and 
acetonitrile in the ratio 50:50 at 1.0 ml/min flow at ambient temperature; it was observed 
that impurity E and impurity D peaks of Ramipril were merging with Metoprolol and 
Atorvastatin peaks. Modification of the buffer and acetonitrile ratio to 55:45 resulted the 
separation of impurity E and impurity D from Metoprolol and Atorvastatin peaks, but 
Ramipril peak was asymmetric i.e. peak tailing observed more than 2.0. The increase in 
the column temperature from ambient to 40°C resulted in achieving the peak symmetry 
and the separation all three analyte peaks AT, RM and MT from impurity peaks, but the 
observed runtime is more i.e. 45 min.  
To reduce the runtime further, the above HPLC method is verified in UPLC using Zorbax® 
Eclipse plus-C8, 2.1 mm x 50 mm, 1.8 μm with flow rate of 0.6 ml/min. On UPLC, the 
runtime is reduced to 10 minutes but the peak symmetry was failing for Metoprolol peak 
i.e. tailing more than 2.0. To improve the peak symmetry for MT, column was changed to 
Zorbax® XDB-C18, 4.6 mm x 50 mm, 1.8 μm with a flow rate 1.0 ml/min, and column 
temperature is maintained at 55°C. The chromatographic separation was achieved by 
following isocratic program using buffer as 0.06% ortho phosphoric acid in Milli Q® water 
having an ion pair reagent 0.045 M sodium lauryl sulfate; buffer and acetonitrile in the ratio 
of 50:50 (v/v). The retention times of MT, AT and RM are 1.324 min, 2.148 min and 2.684 
min respectively. This method is capable to separate all impurities (two known degradants 
of Atorvastatin, four known degradants of Ramipril and two known degradants of 
Metoprolol) from its analyte peaks within 5 minutes. 
The typical overlay chromatogram of blank and standard is shown in Fig. 3. The typical 
overlay chromatogram of placebo and test is shown in Fig. 4. The Spiked chromatogram of 
AT, RM and MT along with impurities is shown in Fig. 5. 
 
Fig. 3.   Overlay chromatogram of blank and standard, extracted at 210nm for RM, AT 
and MT 826  R. K. Seshadri et al.:  
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Fig. 4.   Overlay chromatogram of Placebo and Test, extracted at 210nm for RM, AT 
and MT 
 
Fig. 5.   Spiked chromatogram of AT, RM and MT along with impurities. 
The system suitability parameters (see Table 1) indicate that the method meets the 
preliminary requirements and hence ready to be subjected for validation. 
Tab. 1.   System suitability results 
System suitability parameters  Metoprolol Atorvastatin  Ramipril 
Retention times min  1.310  2.252  2.661 
Theoretical plates  7638  8581  4958 
Asymmetric factor   1.5  1.1  1.1 
Resolution   –  10  4 
 
The details of method validation, as per ICH guidelines [34] are presented in the following 
sections. 
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Method Validation 
Specificity 
The samples have been subjected to degradation such as refluxed with 0.1N HCl for 30 
min at 60°C, refluxed with 0.1 N NaOH for 30 min at 60°C, refluxed with 3% peroxide for 
30 min at 60ºC, exposed to dry heat at 105°C for 15 h, refluxed for 1 hour at 60°C in water, 
exposed to visible light of 1.2 million lux hours, UV light of 200 watt hours m
−2 and 
exposed to 90% relative humidity at 25°C for 7 days (Table 2). 
Tab. 2.   Forced degradation data 
% Degradation  Degradation conditions 
Metoprolol Atorvastatin Ramipril 
Exposed to Visible light for about 1,200 K lux 0.2  0.9  1.5 
Exposed to UV for 200 Watt hours m 
−2 0.1 0.6  0.3 
Exposed to humidity at 25 °C, 90% RH for 
about 7 days  0.0 1.2  1.4 
Refluxed with purified water for about 1 hour 
at 60 °C  0.1 0.9  0.7 
Refluxed with 0.1 N HCI solution for about 
30 min at 60 °C  0.0 1.2  2.7 
Refluxed with 0.1 N NaOH solution for about 
30 min at 60 °C  0.1 0.7  2.6 
Refluxed with 3% H2O2 solution for about 30 
min at 60 °C  0.3 2.2  4.8 
Exposed to dry heat for about 15 hours at 
105 °C  0.4 32.3  33.5 
 
Degradation was not observed in visible light, UV, humidity and water hydrolysis stress 
studies. Significant degradation was not shown in acid hydrolysis, base hydrolysis and 
oxidative conditions. However, thermal stress showed significant degradation. It is 
interesting to note that all the peaks due to degradation are well resolved from the peaks 
of MT, AT &RM (Fig. 6). Further the peak purity of MT, AT & RM was found to be 
homogeneous based on the evaluation parameters such as purity angle and purity 
threshold using Waters Empower Networking Software. The verification of peak purity 
indicates that there is no interference from degradants, facilitating error-free quantification 
of MT, AT and RM. Thus, the method is considered to be “Stability-indicating”.  
Linearity 
The linear regression analysis of MT, AT and RM was constructed by plotting the 
concentration of each analyte versus peak area. The calibration curves were linear in the 
range of 105-840 µg/ml, 20-160 µg/ml and 10-80 µg/ml for MT, AT and RM respectively. 
The linear regression equations are given below. 
MT: Y = 2033.264 conc. + 5139.971 (r
2= 0.9996) 
AT: Y = 7928.515 conc. + 5806.824 (r
2= 0.9998) 
RM: Y = 4045.254 conc. +   339.373 (r
2= 0.9995) 828  R. K. Seshadri et al.:  
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Precision 
The precision of test method was evaluated by analyzing six samples of MT, AT and RM 
capsules. The % RSD of assay of three analytes during precision was found to be less 
than 2%. The results are shown in Table 3, which indicates that the method is precise. 
Tab. 3.   Precision of the method 
% Assay  S.NO. 
Metoprolol Atorvastatin Ramipril 
1. 101.9  102.4  102.2 
2. 101.5  101.7  100.4 
3. 102.0  102.0  101.7 
4. 101.3  102.3  102.3 
5. 102.3  102.1  100.4 
6. 102.3  102.3  101.5 
Average 101.9  102.1  101.4 
% RSD  0.4  0.3  0.8 
Accuracy 
Recovery study of MT, AT and RM from spiked placebo is conducted. Samples are 
prepared by mixing placebo with MT, AT and RM raw material equivalent to about 20%, 
50%, 80%, 100%, and 160% of the assay of nominal sample concentration. Sample 
solutions are prepared in triplicate for each spike level as described in the sample 
preparation. The % mean recoveries of individual analyte from formulation samples were 
found to be satisfactory. The summary of % recovery was mentioned in Table 4. 
Tab. 4.   Accuracy of the method 
Accu-
racy 
level 
MT 
Added 
(mg) 
MT 
Recov.
a 
(%) 
Mean 
MT  
(%) 
AT 
Added
(mg) 
AT 
Recov.
a
(%) 
Mean 
AT  
(%) 
RM 
Added 
(mg) 
 
RM 
Recov.
a 
(%)
 
 
Mean
RM 
(%) 
20%   99.960  101.0   20.565 101.6  10.283  100.6 
50% 246.954 101.8    52.036 100.2  26.018 102.0 
80% 392.084 102.1    80.700 102.5  40.350 101.4 
100% 495.629  102.1  102.731 102.4  51.366  101.0 
160% 783.014  102.0 
101.8 
162.870 102.4 
101.8 
81.435 101.0 
101.2
a Mean for three determinations at each level. 
 
Robustness 
To determine the robustness of the developed method, experimental conditions are 
deliberately altered one factor after the other. The effect of change in flow rate (± 0.2 ml), 
organic phase composition (± 5%) and column temperature (± 5°C) on the retention time, 
resolution and asymmetric factor were studied. In all the studies the resolution between 
MT and AT, AT and RM peaks is greater than 2.5, asymmetric factor is less than 2.0 and 
theoretical plates are more than 2500 for MT, AT and RM peaks, which illustrates the 
robustness of the method.  830  R. K. Seshadri et al.:  
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Test solution stability 
The bench top solution stability of test preparation and standard preparation of MT, AT and 
RM was carried out up to 48 hours, no significant change is observed in % assay of MT, 
AT and RM. Hence the test solutions are stable upto 48 hrs. 
Experimental 
Reagents and Materials 
Active pharmaceutical ingredient of MT, AT and RM and it’s impurities were procured from 
bulk manufacturers of Dr Reddy’s Laboratories. Capsule dosage form developed by Dr 
Reddy’s Laboratories, India.  HPLC grade acetonitrile was purchased from Merck, 
Germany. Analytical reagent sodium lauryl sulfate and ortho phosphoric acid were 
purchased from Merck, Germany. High pure water was prepared by using Millipore Milli 
Q® plus purification system. 
Apparatus and chromatographic conditions 
The Waters Acquity UP-LC system with a photo diode array detector was used for method 
development, validation and forced degradation studies. The output signal was monitored 
and processed using Empower software.  
Chromatographic conditions 
The chromatographic column used was a Zorbax® XDB-C18, 4.6 mm * 50 mm, 1.8 μm 
particles. The buffer used was 0.0045 M of sodium lauryl sulfate with 0.06% (1 gm) ortho 
phosphoric acid. Buffer and acetonitrile in the ratio of 50:50 was used as mobile phase. 
The flow rate of the mobile phase was 1.0 ml/min. The column was maintained at 55 °C 
and the wavelength of 210 nm for detection of MT, RM and AT. The injection volume was 
2 μL.  
Preparation of standard solution 
Standard solution was prepared in methanol containing 420 µg ml
−1 of Metoprolol 
succinate, 80 µg ml
−1 of Atorvastatin and 40 µg ml
−1 of Ramipril. Purity of standards used 
is 99.3% as Metoprolol Succinate, 99.3% as Atorvastatin and 99.8% as Ramipril. 
Preparation of Test solution 
Contents of 10 capsules along with capsule shell (each capsule containing 47.5 mg MT, 
10mg AT and 5 mg RM) was transferred into 250 ml dried volumetric flask, 150 ml of 
methanol is added and sonicated for 30 min with intermediate shaking (maintain the 
sonicator temperature between 20°C–25°C), followed by shaking of 15 min. The flask is to 
allowed cool down to room temperature and then diluted to volume with methanol. A part 
of solution is centrifuged to get clear solution. Further 5 ml of clear centrifuged solution is 
transferred into 25 ml volumetric flask and diluted to volume with methanol to obtain 
sample solution concentration of 420 µg/ml, 80 µg/ml and 40 µg/ml respectively.  
Conclusions 
The developed chromatographic assay fulfilled all the requirements to be identified as 
reliable and feasible method, including accuracy, linearity, recovery and precision data. It   Simultaneous Quantitative Determination of Metoprolol, Atorvastatin and Ramipril in Capsules …  831 
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is a highly specific and precise analytical procedure and its chromatographic run time of 
six minutes allows the analysis of a large number of samples in a short period of time. 
Therefore, this HPLC method can be used as a routine sample analysis as well as stability 
testing. The method validation shows satisfactory data for all the method validation 
parameters tested. The developed method is stability-indicating and can be used for 
quantifying Metoprolol, Atorvastatin and Ramipril in capsule dosage form and their 
combinations (i.e. MT+AT; MT+RM, AT+RM and AT+RM+MT). 
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